Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?

Abeygunasekera, Anuruddha M; Jayasinghe, Saroj

doi:10.1016/j.mehy.2020.109843

Cited by 7 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Members of this family are known to result in mild infections. Nevertheless, the outbreaks caused by the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) had significant health outcomes in terms of severity and mortality [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Shoieb,

El-Ghiaty,

El-Kadi

2020

emergent mater.

View full text Add to dashboard Cite

In March 2020, The World Health Organization (WHO) has declared that the coronavirus disease 2019 (COVID-19) is characterized as a global pandemic. As of September 2020, infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to 213 countries and territories around the world, affected more than 31.5 million people, and caused more than 970,000 deaths worldwide. Although COVID-19 is a respiratory illness that mainly targets the lungs, it is currently well established that it is a multifactorial disease that affects other extra-pulmonary systems and strongly associated with a detrimental inflammatory response. Evidence has shown that SARS-CoV-2 causes perturbation in the arachidonic acid (AA) metabolic pathways; this disruption could lead to an imbalance between the pro-inflammatory metabolites of AA including mid-chain HETEs and terminal HETE (20-HETE) and the anti-inflammatory metabolites such as EETs and subterminal HETEs. Therefore, we propose novel therapeutic strategies to modulate the level of endogenous anti-inflammatory metabolites of AA and induce the patient’s endogenous resolution mechanisms that will ameliorate the virus-associated systemic inflammation and enhance the primary outcomes in COVID-19 patients. Also, we propose that using nanoencapsulation of AA and its associated metabolites will contribute to the development of safer and more efficacious treatments for the management of COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Shoieb,

El-Ghiaty,

El-Kadi

2020

emergent mater.

View full text Add to dashboard Cite

show abstract

“…Inhibits viral entry and anti-inflammatory Rilinger et al [43] Perspective Tocilizumab Anti-inflammatory Sarma et al [44] Clinical trial Hydroxychloroquine Blocks viral infection Wilde et al [45] In vitro Cyclosporin A Inhibited coronavirus replication Abeygunasekera et al [46] Brief review Diethylcarbamazine Immune modulatory, enhances antibody production, antiviral activity Biembengut et al [47] In silico approach Coagulation modifiers Targeting SARS-CoV-2 main protease Mpro Irvani et al [48] Perspective Interferon Beta 1a, compared to Interferon Beta 1b Tan et al [49] In [56] Clinical trial Dexamethasone Anti-inflammatory the concentration of the antibodies given and may last for weeks or months. The effectiveness of the sera varies with the type of virus.…”

Section: Results: Convalescent Plasmamentioning

confidence: 99%

An updated review of potential therapeutic agents against COVID-19

Ahmad

Sohail

Chishti

2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease of 2019 (COVID-19) is a public health emergency of international concern caused by a novel coronavirus, i.e., Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Since it is a new virus, an effective remedy against the virus is yet unknown. SARS-CoV-2 is a member of order nidovirales, family coronaviridae. Previously known treatment strategies against Middle East Respiratory Syndrome and Severe Acute Respiratory Syndromes are being tested for their effectiveness against SARS-CoV-2. Thus, various clinical and observational studies aimed at identifying potential therapies against the disease. In our study, we reviewed various drugs along with their mechanism of action, including anti-virals, anti-bacterials, glucocorticoids, ACE inhibitors, anti retrovirals, antimalarials, monoclonal antibodies, plasma, and many more. Individual drugs are described and evaluated for their potential to treat SARS-CoV-2 infection. This study offers a brief review of the findings of trials conducted so far. Dexamethasone, convalescent plasma therapy, tocilizumab, remdesivir, and combination therapies are found to be beneficial against SARS-CoV-2.

show abstract

“…Other antiparasitic drugs such as diethylcarbamazine, niclosamide and nitazoxanide, and hydroxychloroquine and chloroquine have been explored for COVID-19 treatment [37][38][39]. If successful, the widespread use of these drug to fight the pandemic may as well result in resistance.…”

Section: Repurposing Of Antiparasitic Drugs For the Management Of Covid-19mentioning

confidence: 99%

Suboptimal Antimicrobial Stewardship in the COVID-19 Era: IS Humanity Staring at a Postantibiotic Future?

et al. 2021

View full text Add to dashboard Cite

In the absence of potent antimicrobial agents, it is estimated that bacterial infections could cause millions of deaths. The emergence of COVID-19, its complex pathophysiology and the high propensity of patients to coinfections has resulted in therapeutic regimes that use a cocktail of antibiotics for disease management. Suboptimal antimicrobial stewardship in this era and the slow pace of drug discovery could result in large-scale drug resistance, narrowing future antimicrobial therapeutics. Thus, judicious use of current antimicrobials is imperative to keep up with existing and emerging infectious pathogens. Here, we provide insights into the potential implications of suboptimal antimicrobial stewardship, resulting from the emergence of COVID-19, on the spread of antimicrobial resistance.

show abstract

Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?

Cited by 7 publications

References 17 publications

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

An updated review of potential therapeutic agents against COVID-19

Suboptimal Antimicrobial Stewardship in the COVID-19 Era: IS Humanity Staring at a Postantibiotic Future?

Contact Info

Product

Resources

About